Market brief

European Vaccines Landscape 2026: Biodefence, mRNA, Allergen, Infectious Disease

The European vaccines sector in 2026 spans five overlapping tracks: biodefence + public-health vaccines (Bavarian Nordic MVA-BN platform, Statens Serum Institut), mRNA vaccine innovation (BioNTech, CureVac - covered in depth in the European mRNA & Immunotherapy 2026 brief), infectious-disease vaccines (Valneva Sweden, Rokote Laboratories nasal adenoviral, altona Diagnostics for infectious-disease IVD), allergen immunotherapy (ALK-Abelló commercial, Desentum peptide-based, IO Biotech), and clinical-stage + tools + platform operators (Nykode Therapeutics DNA vaccines, Abera Bioscience nasal/OMV, MinervaX maternal Group B Strep, ExpreS2ion protein-expression platform, Valo Therapeutics, Froceth individualised cancer immunotherapy). The directory surfaces 19 vaccine-adjacent operators across Denmark, Sweden, Finland, Norway, Germany, Poland, and Lithuania - plus the two German mRNA innovators covered separately. Denmark hosts 6 vaccine-adjacent operators - the highest Nordic vaccine-cluster operator count the directory surfaces - with Bavarian Nordic + ALK-Abelló + Statens Serum Institut + ExpreS2ion + MinervaX + IO Biotech. The European mRNA & Immunotherapy 2026 brief covers the mRNA layer in detail.

Summary

Key findings

Bavarian Nordic (Kvistgaard, Denmark) operates the European MVA-BN vaccine platform with regulatory approval for smallpox, monkeypox, and related biodefence use - the directory-anchor biodefence operator.
The Danish vaccine + immunotherapy cluster is the highest single-country vaccine-operator count the directory surfaces (6), with Bavarian Nordic, ALK-Abelló, Statens Serum Institut, ExpreS2ion, MinervaX, and IO Biotech all in Denmark.
Nasal and non-injectable vaccine platforms run through Rokote Laboratories (Kuopio, nasal adenoviral-vector COVID-19 and respiratory programmes, Phase 1 scope) and Abera Bioscience (Uppsala, nasal OMV platforms and infectious-disease).
Allergen immunotherapy concentrates at ALK-Abelló (Horsholm, commercial-scale allergen-immunotherapy manufacturing) alongside Desentum (Espoo, peptide-based allergen immunotherapy) - a European specialty the directory surfaces at clinical + commercial scope.
First-pass shortlist

Choose the vaccine relationship before choosing an operator

Vaccine manufacturers, public-health institutions, platform developers, and external CDMOs have different roles. Start with the programme need and confirm product rights, manufacturing scope, regulatory status, and external availability directly.

Commercial vaccine product or supply

A marketed-vaccine manufacturer

Denmark and Sweden

Publicly stated scope
Treat Bavarian Nordic or Valneva as commercial vaccine companies when the question concerns their public product portfolios, supply, or a specific commercial relationship.
Confirm first
Specific product, market, regulatory status, distribution rights, supply terms, pharmacovigilance responsibility, and appropriate commercial contact.
Do not assume
That a marketed vaccine manufacturer is a general external CDMO or has product availability in every country.
Vaccine or viral-vector CDMO

External development, manufacture, or fill-finish route

Germany, Finland, and Poland

Publicly stated scope
Start with IDT Biologika for publicly described vaccine and vector manufacturing, then use the Viral Vector and Sterile Fill-Finish guides to test the specific modality and product path.
Confirm first
Vaccine type, antigen or vector, development stage, containment, GMP scope, presentation, fill-finish, analytical release, scale, and named site.
Do not assume
That vaccine-manufacturing wording confirms an open, matching external campaign or all required drug-substance and drug-product steps.
Clinical vaccine or platform collaboration

Nasal, OMV, maternal, DNA, or expression-platform developer

Finland, Sweden, Denmark, and Norway

Publicly stated scope
Treat Rokote Laboratories, Abera Bioscience, MinervaX, Nykode, ExpreS2ion, and related operators as programme or platform collaboration candidates based on disclosed activity.
Confirm first
Target pathogen or indication, platform rights, clinical evidence, programme stage, manufacturing dependencies, collaboration model, territory, and whether access is open.
Do not assume
That a public vaccine platform offers contract manufacturing, a licensed product, or immediate external partnership access.
Allergen immunotherapy

Commercial or clinical allergy-treatment route

Denmark and Finland

Publicly stated scope
Route commercial allergen-immunotherapy questions to ALK-Abelló and clinical or platform discussions to Desentum, according to the stated product and development context.
Confirm first
Allergen, route of administration, market, evidence stage, regulatory pathway, supply versus collaboration intent, and medical or commercial contact.
Do not assume
That allergen-immunotherapy expertise is interchangeable with infectious-disease vaccine development or an external CDMO offer.
Public-health or preparedness infrastructure

Reference laboratory, surveillance, or preparedness institution

Copenhagen, Denmark

Publicly stated scope
Use Statens Serum Institut where a programme needs a public-health, surveillance, reference-laboratory, or preparedness context rather than a commercial manufacturing partner.
Confirm first
Public-health objective, jurisdiction, data or sample needs, applicable authority, research versus service relationship, and appropriate institutional route.
Do not assume
That a national reference institute functions as a commercial CDMO, product supplier, or private-sector licensing partner.
Numbers

Quick numbers

Vaccine-adjacent operators19Plus BioNTech + CureVac (mRNA, covered separately)
Biodefence anchorBavarian NordicMVA-BN platform, Kvistgaard Denmark
Allergen immunotherapy anchorALK-AbellóHorsholm Denmark, commercial scale
Danish vaccine cluster6 operatorsHighest Nordic vaccine-operator count the directory surfaces
Analysis

Biodefence and public-health vaccines: Bavarian Nordic + Statens Serum

Denmark concentrates the European biodefence vaccine anchor through Bavarian Nordic (Kvistgaard). The MVA-BN platform holds regulatory approval for smallpox and monkeypox use in the US (JYNNEOS), EU (IMVANEX), and Canada (IMVAMUNE), and serves as the biodefence backbone for government stockpiling programmes. Bavarian Nordic also operates next-generation biodefence + travel-vaccine platforms and post-pandemic-era public-health programmes. Statens Serum Institut (Copenhagen) runs as Denmark’s national public-health reference lab and vaccine-related infrastructure, coordinating infectious-disease surveillance, reference laboratory services, and vaccine-preparedness workflows with the Danish Medicines Agency. For sponsors running biodefence or public-health vaccine programmes in Europe, Bavarian Nordic is the primary directory anchor and SSI is the reference-lab partner.

Analysis

Infectious-disease vaccines: Valneva, Rokote, regional operators

Valneva Sweden (Stockholm) operates as the European infectious-disease vaccine manufacturer with commercial products in travel + routine vaccination (IXIARO Japanese encephalitis, DUKORAL cholera, IXCHIQ chikungunya, plus a pipeline across Lyme disease and beyond). Rokote Laboratories Finland (Kuopio) develops nasal adenoviral-vector vaccines for COVID-19 and respiratory programmes at Phase 1 clinical scope. Synthaverse (Lublin, Poland) runs pharmaceutical + vaccine manufacturing as a Polish domestic operator. Germany adds IDT Biologika (Dessau-Rosslau) which operates viral vaccines + cell-and-gene-therapy + fill-finish CDMO at commercial scale. For sponsors running infectious-disease vaccine programmes, these four operators cover the directory-visible European manufacturing + development layer.

Analysis

Allergen immunotherapy and tolerance-based vaccines

ALK-Abelló (Horsholm, Denmark) operates European allergen immunotherapy manufacturing at commercial scale, with standardised allergen-vaccine products for house dust mite, grass pollen, and related allergens. Desentum (Espoo, Finland) develops peptide-based allergen immunotherapy as a next-generation platform for clinical-stage allergy treatment. IO Biotech (Copenhagen, Denmark) runs immune-modulating vaccines that sit between traditional immunotherapy and cancer-vaccine approaches. Combined with the tolerance-based cell therapy operators covered in the Cell & Gene Therapy Europe 2026 brief (PolTREG, TolerogenixX), this forms the European tolerance-and-allergen vaccine layer.

Analysis

mRNA vaccines: the German innovation core

mRNA vaccines concentrate in the German innovation core with BioNTech (Mainz) and CureVac (Tübingen). BioNTech shifted to large-scale commercial mRNA vaccine manufacturing during the COVID era (Comirnaty / BNT162b2 with Pfizer) and now runs infectious-disease and oncology mRNA programmes across its pipeline. CureVac operates an RNA platform with translational and clinical-development activity. The European mRNA supply chain (AGC Biologics Heidelberg mRNA + pDNA CDMO, BioSpring Frankfurt oligonucleotide API, IDT Biologika viral vectors) supports this layer. For the full mRNA supply chain story, the European mRNA & Immunotherapy 2026 brief is the dedicated read.

Analysis

Clinical-stage vaccine innovators and platform biotechs

Around the established anchors, the directory surfaces a clinical-stage vaccine and platform layer. Nykode Therapeutics (Oslo, formerly Vaccibody) operates a DNA-vaccine and immunotherapy platform. Abera Bioscience (Uppsala) develops nasal and OMV (outer membrane vesicle) vaccine platforms for infectious disease. MinervaX (Frederiksberg, Denmark) runs maternal immunisation programmes for Group B Streptococcus. ExpreS2ion Biotechnologies (Horsholm) provides protein-expression + vaccine R&D + antigen-production platforms (used by malaria-vaccine developers and others). Valo Therapeutics (Helsinki) runs oncolytic virus + vaccine-vector + cancer-immunotherapy programmes. Froceth (Vilnius) develops adipose-derived individualised cancer-immunotherapy ATMPs. Together with Bavarian Nordic + Valneva + ALK-Abelló + Rokote + Desentum, these nine operators cover the clinical-stage + platform European vaccine innovator layer.

Analysis

Infectious-disease diagnostics adjunct

Vaccine programmes need matching diagnostic capacity. The directory surfaces three operators with infectious-disease IVD scope sitting adjacent to the vaccine layer: altona Diagnostics (Hamburg, Germany, real-time PCR assays for global infectious-disease testing), ORGENTEC Diagnostika (Mainz, infectious-disease + autoimmune testing), and ArcDia International (Turku, Finland, automated near-patient infectious-disease IVD). Abacus Diagnostica (Turku) adds rapid PCR sample-to-answer systems for infectious-disease testing. For sponsors running vaccine clinical trials that need matched diagnostic endpoints, these four operators form the European infectious-disease IVD layer - see the European Diagnostics Landscape 2026 brief for the full diagnostics context.

Analysis

Regulation and funding in 2026

European vaccine regulation runs through EMA centralised approval (Committee for Medicinal Products for Human Use + EMA Emergency Task Force for public-health emergencies). Biodefence stockpiling programmes run through HERA (Health Emergency Preparedness and Response Authority, established 2021). Clinical-trial authorisation runs under CTIS + the Clinical Trials Regulation. GMP compliance is mandatory for commercial manufacturing; GDP compliance covers cold chain and distribution (see the European Pharma Cold Chain & GDP Logistics 2026 brief). EU-internal biodefence funding is being restructured under the Biotech Act + Biotech & Biomanufacturing Hub strategy. The EU Biotech Regulation 2026 brief covers the wider regulatory context for vaccines + biologics + AI.

What to watch

What to watch next

Bavarian Nordic commercial MVA-BN capacity + next-generation biodefence announcements
Valneva Sweden infectious-disease vaccine pipeline (chikungunya, Lyme disease)
BioNTech mRNA oncology pipeline progression beyond the Comirnaty franchise
Nykode Therapeutics DNA-vaccine clinical progression
Rokote Laboratories nasal adenoviral-vector clinical milestones
HERA-coordinated EU biodefence stockpiling contracts
FAQ

Frequently asked questions

Who are the main European vaccine manufacturers in 2026?

Bavarian Nordic (Kvistgaard, Denmark) operates the MVA-BN biodefence platform with commercial products for smallpox/monkeypox. ALK-Abelló (Horsholm, Denmark) runs allergen immunotherapy at commercial scale. Valneva Sweden (Stockholm) manufactures infectious-disease vaccines (Japanese encephalitis, cholera, chikungunya). BioNTech (Mainz, Germany) runs large-scale mRNA vaccine manufacturing (Comirnaty with Pfizer). Statens Serum Institut (Copenhagen) anchors Denmark’s national public-health reference infrastructure. IDT Biologika (Dessau-Rosslau, Germany) runs viral vaccines + cell-and-gene therapy + fill-finish at commercial scale.

Where is European biodefence vaccine capacity concentrated?

Bavarian Nordic (Kvistgaard, Denmark) is the European biodefence vaccine anchor the directory surfaces, with the MVA-BN platform approved for smallpox, monkeypox, and related uses (JYNNEOS in the US, IMVANEX in the EU). HERA (Health Emergency Preparedness and Response Authority, EU, established 2021) coordinates EU biodefence stockpiling programmes. Statens Serum Institut (Copenhagen) adds Denmark’s national public-health + reference-laboratory infrastructure.

What clinical-stage vaccine innovators operate in Europe in 2026?

Nykode Therapeutics (Oslo, DNA vaccines + immunotherapy). Abera Bioscience (Uppsala, nasal + OMV vaccines). MinervaX (Frederiksberg, maternal immunisation for Group B Strep). ExpreS2ion (Horsholm, protein-expression + vaccine R&D + antigen-production platforms). Rokote Laboratories (Kuopio, nasal adenoviral-vector respiratory vaccines at Phase 1). Valo Therapeutics (Helsinki, oncolytic virus + vaccine-vector + cancer-immunotherapy). Desentum (Espoo, peptide-based allergen immunotherapy). IO Biotech (Copenhagen, immune-modulating vaccines). Froceth (Vilnius, individualised cancer immunotherapy ATMPs).

How does European vaccine regulation work in 2026?

Vaccines in the EU go through EMA centralised approval via the Committee for Medicinal Products for Human Use (CHMP), with the EMA Emergency Task Force handling public-health emergencies. Clinical trials submit through CTIS under the Clinical Trials Regulation. GMP compliance is mandatory for commercial manufacturing; GDP compliance covers cold chain and distribution (see the European Pharma Cold Chain & GDP Logistics 2026 brief). HERA (Health Emergency Preparedness and Response Authority, established 2021) coordinates EU biodefence stockpiling. See the EU Biotech Regulation 2026 brief for the wider regulatory context.

Where is the European mRNA vaccine supply chain?

mRNA vaccines concentrate in Germany: BioNTech (Mainz) for commercial-scale mRNA and CureVac (Tübingen) for clinical-development RNA platforms. The supporting supply chain covers AGC Biologics Heidelberg (mRNA + pDNA CDMO), BioSpring Frankfurt (oligonucleotide GMP supply), IDT Biologika (viral vectors alongside viral vaccines), and Bachem (Bubendorf, Switzerland, synthetic peptide + oligonucleotide API). For the full mRNA supply-chain map, the European mRNA & Immunotherapy 2026 brief is the dedicated read.

Methodology note

Sources and interpretation

Sources: verified Memel Biotech directory entries for every vaccine + immunotherapy operator, official company disclosures, EMA + HERA public materials, and editorial comparison against the European mRNA & Immunotherapy 2026, Nordic Biotech Landscape 2026, and EU Biotech Regulation 2026 briefs. The directory entry for each operator links to the authoritative company sources.

Disclaimer

Use limits

This brief is an editorial map of visible European vaccine + immunotherapy activity in 2026. It does not rank operators, certify any regulatory status beyond public disclosures, or disclose non-public capacity - sponsors should verify directly with each operator before engagement.

Primary sources

Source list

Bavarian Nordic MVA-BN platformALK-Abelló allergen immunotherapyValneva infectious-disease vaccinesStatens Serum Institut (Denmark)EU HERA (Health Emergency Preparedness and Response Authority)
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home